Immune checkpoint inhibitor (ICI) combinations have a significant survival benefit over the tyrosine kinase inhibitor (TKI) sunitinib and should be made available to patients with advanced renal cell carcinoma (RCC), according to a systematic review.

Until recently, first-line therapy for RCC has primarily been TKIs that target vascular endothelial growth factor (VEGF) and other receptors,...